Company intelligence / Profile preview

步长制药

Ownership: Private
Development stage: Other

Overview

步长制药 has several leading commercialized products in China’s prescription drug market, especially in the field of cardiovascular and cerebrovascular diseases. Its flagship drugs—such as Naoxintong capsule, Wenxin granule, Danhong injection—are widely used and have established strong brand recognition. The company also maintains a robust R&D pipeline with nearly 180 projects under development as of recent reports.

Therapeutic areas: Infectious DiseasesWomen's HealthNeurologyCardiovascular
Modalities: Small moleculeBiologic (including traditional Chinese medicine formulations)Vaccine
Industry: Biotech

Partnerships

Not specifically disclosed; company has broad collaborations within the Chinese healthcare sector.

Beyond the preview

Go deeper on 步长制药.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 步长制药.

Explore the full profile